NN-414. Novo Nordisk.
Novo Nordisk is developing NN-414, an orally active beta-cell-selective regulator of insulin release, for the potential treatment of type 1 and type 2 diabetes. Phase 1 efficacy trials were underway by November 2000; these trials were ongoing in February 2002 and had been concluded by February 2003.
Choi
Joong-Kwon
JK
Korea Research Institute of Chemical Technology, Medicinal Science Division, 100 Jang-dong, Yuseong-gu, 305-343 Daejeon-si, Korea. jkchoi@pado.krict.re.kr
D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D000075202:Contraindications; D003499:Cyclic S-Oxides / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D019086:Bridged Bicyclo Compounds, Heterocyclic; D003499:Cyclic S-Oxides; D007004:Hypoglycemic Agents; C475618:NN 414